Physician profile
Aaron Patrick Noles
NPI 1982066346
$1,578.77
in general payments reported to CMS, 2019-2025
28 companies · $372 in 2025
The $372 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $926 · 2023: $48.27 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $395.36 | 2021-2025 | |
| Grt US Holding, INC. | $138.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $116.05 | 2021-2025 | |
| Amgen INC. | $86.45 | 2021-2022 | |
| Lundbeck LLC | $80.88 | 2022-2025 | Vyepti |
| Lilly USA, LLC | $64.97 | 2021-2023 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $60.67 | 2022 | |
| Genzyme Corporation | $59.16 | 2021-2022 | |
| Allergan, INC. | $58.44 | 2021 | |
| Pfizer INC. | $52.88 | 2025 | |
| Genentech USA, INC. | $49.75 | 2022 | |
| Biogen, INC. | $49.58 | 2022 | |
| Acorda Therapeutics, INC | $43.21 | 2022-2023 | Inbrija |
| Acadia Pharmaceuticals INC | $38.01 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $33.52 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $26.85 | 2025 | Symbravo |
| Argenx US, INC. | $25.88 | 2022 | |
| Ucb, INC. | $23.58 | 2022 | |
| Greenwich Biosciences, INC. | $23.40 | 2021 | |
| Csl Behring | $19.53 | 2022 | |
| Grifols USA, LLC | $18.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.56 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.27 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.84 | 2023 | Ponvory |
| Janssen Biotech, INC. | $15.74 | 2025 | |
| Avion Pharmaceuticals | $14.74 | 2022 | |
| Impel Pharmaceuticals INC. | $14.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Noles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.